MSDS: Physostigmine Salicylate Injection, 0.1%

Manufacturer: Akorn Pharmaceuticals
1925 West Field Court, Suite 300
Lake Forest, IL 60045

Contact Telephone: 1-800-932-5676
Email: customer.service@akorn.com

Section 1 - IDENTIFICATION

Common/Trade Name: Physostigmine Salicylate Injection, 0.1%
Common Name of Active Ingredient: Physostigmine Salicylate, Eserine salicylate
Chemical Formula: C_{15}H_{21}N_3O_2 \cdot C_7H_6O_3
Legal Category: Prescription only

Section 2 – HAZARD(S) IDENTIFICATION

Routes of Entry: For intramuscular or intravenous injection
Physostigmine salicylate is toxic to the nervous system.

Potential Health Hazards:
Mutagenicity: NA
Teratogenicity: NA
Developmental toxicity: NA
Eye: Very hazardous, irritant.
Skin: Slightly Hazardous, irritant.
Ingestion: Extremely hazardous.
Inhalation: Very hazardous.

Carcinogenicity:
National Toxicology Program (NTP): No
International Agency for Research on Cancer (IARC): No
Occupational Safety and Health Administration (OSHA): No
American Conference of Governmental Industrial Hygienists (ACGIH): NE
Environmental Protection Agency (API): NE
Section 3 – COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Component</th>
<th>CAS</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physostigmine Salicylate, USP</td>
<td>57-64-7</td>
<td>0.1 %</td>
</tr>
<tr>
<td>Sodium Metabisulfite, NF</td>
<td>7681-57-4</td>
<td>0.1 %</td>
</tr>
<tr>
<td>Benzyl Alcohol, NF</td>
<td>100-51-6</td>
<td>2.0 %</td>
</tr>
<tr>
<td>Water for Injection, USP</td>
<td>7732-18-5</td>
<td>QS</td>
</tr>
</tbody>
</table>

Section 4 – FIRST AID MEASURES

**Eye Contact:** Flush eyes with copious quantities of water for at least 15 minutes. Seek medical attention.

**Skin Contact:** May cause irritation. Product may be absorbed through the skin. Remove contaminated clothing and clean before reuse. Wash with soap and water. Get medical attention.

**Inhalation:** Move individual to fresh air. Get medical attention immediately.

**Ingestion:** Flush mouth with water. Seek immediate medical attention. **May be fatal if swallowed.**

Section 5 – FIRE FIGHTING MEASURES

**Flash Point:** Not Established

**Auto ignition:** Not Available

**Lower Explosion Limit:** Not Established

**Upper Explosion Limit:** Not Established

**Fire Hazards in Presence of Various Substances:**

**Risk of explosion of the product in presence of mechanical impact:** NA

**Risk of explosion of the product in presence of static discharge:** NA

**General Hazard:** Not Established

**Fire Fighting Instructions:** Use water, carbon dioxide, dry chemical, foam, or Halon. Do not use water jet. Solution thermally decomposes to form toxic vapors. Use caution.

**Fire Fighting Equipment:** Firefighters should wear self-contained breathing apparatus and full protective gear.

**Hazardous Combustion Products:** Toxic Fumes may be emitted.
Section 6 – ACCIDENTAL RELEASE MEASURES

Use of personal protective equipment such as gloves, lab coat, splash goggles, dust respirator is recommended. Contain any spills to prevent drainage into sewers or streams. Absorb spilled solution with suitable materials such as clay absorbent or absorbent pads for aqueous solutions. Wipe working surfaces to dryness then wash with soap and water.

Dispose of all waste in accordance with federal, state and local regulations.

Section 7 – HANDLING AND STORAGE

KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.
General Handling: No special protective equipment or procedures are required in the clinical or home environment. As a general rule, while handling pharmaceutical products, avoid all contact and inhalation of mists or vapors associated with the product. Avoid contact with skin, eyes, clothing. Do not mix with other drugs.

Storage Conditions: Store at controlled room temperature 20º to 25ºC (68º to 77º F)

Section 8 – EXPOSURE CONTROLS / PERSONAL PROTECTION

Engineering Controls: Local exhaust or general ventilation is recommended.

Personal Protective Equipment
- Eye Protection: Wear chemical splash goggles or safety glasses.
- Hand Protection: When administering this product to patients, wear nitrile or latex gloves.
- Respiratory Protection: Under normal conditions of product use, respiratory protection is not required. Wear appropriate respirator when ventilation is inadequate.
- Ventilation: Local exhaust recommended.
- Contaminated Equipment: Wash contaminated clothing and equipment with soap and water. Release rinse water in accordance with federal, state and local regulations.
- Skin Protection: Use coveralls, booties and gloves for clean-up activities.

Section 9 – PHYSICAL / CHEMICAL CHARACTERISTICS

- Physical Form/ Appearance: Clear, colorless solution
- Boiling Point/Boiling Range: NE
- Melting Point/Melting Range: Not Applicable
- Freezing Point: Aqueous
- Vapor Pressure: Not Established
- Relative Vapor Density: Not Established
- Percent Volatiles: Not Established
- Viscosity: Comparable to water
- Osmolality: Not Established
**MSDS: Physostigmine Salicylate Injection, 0.1%**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH</td>
<td>2.2 to 5.0</td>
</tr>
<tr>
<td>Molecular Weight</td>
<td>413.47 g/mole for active pharmaceutical ingredient</td>
</tr>
<tr>
<td>Solvent Solubility</td>
<td>Soluble in water and ethanol</td>
</tr>
<tr>
<td>Specific Gravity</td>
<td>~1.00 @ 25°C</td>
</tr>
<tr>
<td>Latex Free</td>
<td>Yes</td>
</tr>
</tbody>
</table>

**Section 10 – STABILITY AND REACTIVITY**

- **Reactivity:** Not Established
- **Chemical Stability:** Stable at normal temperatures and pressures
- **Possibility of Hazardous Reactions:** May be reactive with strong oxidizing agents
- **Hazardous Polymerization:** Will not occur
- **Conditions to avoid:** Exposure to light and air.

**Section 11 – TOXICOLOGICAL INFORMATION**

- **Signs/Symptoms of Exposure & Overexposure:** Can cause a cholinergic crisis. Appropriate antidote is atropine sulfate
- **Medical Conditions Aggravated by Accidental Exposure:** Not Established
- **Acute Effects**
  - Oral LD$_{50}$: 2.5 mg/kg, in mice
  - Intraperitoneal LD$_{50}$: 0.64 mg/kg, in mice

**Chronic Effects**

- **Organ Systems:** Toxic to the central nervous system
- No adequate and well controlled studies in humans have been conducted to fully determine the mutagenic, teratogenic or adverse reproductive effects of physostigmine salicylate. Classified as Pregnancy Category C.

**Usage in Pregnancy:**

Safe use in pregnancy and lactation has not been established; therefore use in pregnant women, nursing mothers or women who may become pregnant requires that possible benefits be weighed against possible hazards to mother and child.

**Adverse reactions:**

Nausea, vomiting and salivation can be offset by reducing dosage. Bradycardia, respiratory distress and convulsions may occur if intravenous administration is too rapid. Can cause cholinergic crisis.
Section 12 – ECOLOGICAL INFORMATION

Ecotoxicity: Not Established
Mobility in Environment: Applicable volatilization into the air is not expected. Product administered to patients presents a negligible impact on the environment.

Section 13 – DISPOSAL INFORMATION

Disposal Procedure: Dispose of material according to Federal, State, and Local regulations

Section 14 – TRANSPORTATION INFORMATION

UN/NA Number: 1851
Proper Shipping Name: Medicine, liquid, toxic, n.o.s.
DOT Hazard Class: Class 6.1 - poisonous material
Packaging Group PGII

Section 15 – REGULATORY INFORMATION

Right to Know: Pennsylvania, Massachusetts
FDA (Food & Drug Administration): Prescription only
NDC No. 17478-510-02 (2 ml)

TSCA (Toxic Substance Control Act): 8b Inventory
SARA: 302/304/311/312 extremely hazardous substance

HMIS (Hazardous Materials Information System (USA)):
Health Hazard 4
Fire Hazard 1
Reactivity Hazard 0

National Fire Protection Association (NFPA):
Health Hazard 4
Fire Hazard 1
Reactivity Hazard 0

WHMIS (Workplace Hazardous Materials):
Class D-1A, D-2B
Very Toxic

CERCLA: Hazardous Substance
DSCL: R41 – Risk of serious damage to eyes
OSHA: This material is considered hazardous by definition within Hazard Communications Standard 29CFR 1910.1200.
Section 16 – OTHER INFORMATION

Date of preparation or last revision: 09-2013

Disclaimer: This document is generated to distribute health, safety and environmental data. It is not a specification sheet and none of the displayed data should be construed as a specification. Information on this MSDS sheet was obtained from sources which we believe are reliable, and we believe that the information is complete and accurate. However, the information is provided without any warranty, express or implied, regarding its correctness. Some of the information presented and conclusions drawn are from sources other than direct test data of the substance. The conditions or methods of handling, storage, use and disposal of the product are beyond our control and may also be beyond our knowledge. It is the user’s responsibility to determine the suitability of any material for a specific purpose and to adopt such safety precautions as may be necessary. If the product is used as a component in another product, this MSDS information may not be applicable. For these reasons, we do not assume any responsibility and expressly disclaim liability for any loss, damage or expense arising out of or in any way connected with the handling, storage, use or disposal of this product.